Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Improving maintenance treatment adherence for adults with eosinophilic esophagitis

Official title: An Intervention Study to Improve Therapeutic Compliance in Adult Patients With Eosinophilic Esophagitis.

Run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · NCT05730933 · Data updated 2026-11-12

This project will test whether extra education plus more frequent follow-up and reminders help adults with eosinophilic esophagitis stick to their long-term medications.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment72 (estimated)
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Academic / other
Locations1 site (Amsterdam)
StatusRecruiting
StartedApril 12, 2023
Main results expectedDecember 2025
Study endsDecember 2025
Registry record updatedMay 31, 2025
Trial IDNCT05730933 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18 years) with biopsy-confirmed eosinophilic esophagitis (>15 eos/hpf) who are currently on or about to start PPI or swallowed topical corticosteroid maintenance therapy.

Probably not a fit

Patients who require esophageal dilation, have severe unstable comorbidities, are receiving other investigational treatments, or cannot read Dutch or English are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Investigators will test whether providing extra education combined with more frequent follow-up visits and patient reminders improves long-term adherence to maintenance medication in adults with eosinophilic esophagitis. Eligible participants are adults with histologically confirmed EoE (>15 eosinophils per high power field) who are on or starting maintenance therapy with a proton pump inhibitor or swallowed topical corticosteroids. The intervention offers additional education, closer monitoring, and reminder prompts while the comparator receives usual care and standard information. Adherence will be tracked over time using medication records and follow-up contacts to determine whether the enhanced support increases persistence with therapy.

Why it matters

Potential benefit: If successful, this approach could help patients stay on maintenance medication more consistently, reducing symptoms and the risk of complications or urgent care visits.

How similar studies have gone: Behavioral, educational, and reminder-based programs have improved medication adherence in many chronic diseases, but direct evidence in eosinophilic esophagitis is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Written informed consent
* Male or female patient
* Age \>18 years
* Previous diagnosis of EoE, confirmed by histopathology, with the presence of \>15 eosinophilic granulocytes per high power field (hpf) in esophageal biopsies
* Current maintenance treatment for EoE with a PPI or swallowed topical corticosteroids or about to start with these maintenance medications as decided during regular clinical practice

Exclusion Criteria:

* Severe and clinically unstable concomitant disease that may interfere with the subject's ability to participate in the study
* Receive investigational treatment during the study
* Dilation of esophagus required
* Insufficient Dutch or English language skills to understand patient information leaflets

Where it's running

  • Amsterdam UMC, location AMC
    Amsterdam, Netherlands
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.